乌司奴单抗治疗慢性储袋炎的有效性与安全性:一项前瞻性开放标签多中心研究
本前瞻性开放标签多中心研究纳入22例慢性储袋炎患者,基线静脉给予乌司奴单抗约6 mg/kg,此后每8周皮下注射90 mg。第16周27.3%、第48周36.4%的患者达到无激素缓解,第16周和第48周分别有54.5%的患者达到应答,mPDAI中位数由基线8降至第16周7、第48周4。
要点
- 第16周27.3%、第48周36.4%的患者达到无激素缓解
- 第16周和第48周均有54.5%的患者达到应答
- mPDAI中位数由基线8降至第48周4(P < .001)
核心结论
- 乌司奴单抗对约一半的慢性储袋炎患者有效,因此应将其纳入慢性储袋炎的治疗流程。
研究设计与样本
- 前瞻性开放标签多中心研究;纳入22例慢性储袋炎患者(59%男性,中位年龄42.2岁);基线静脉给予乌司奴单抗约6 mg/kg,此后每8周皮下注射90 mg;在第16周和第48周评估改良储袋炎疾病活动指数(mPDAI)。
主要发现
- 第16周27.3%、第48周36.4%的患者达到无激素缓解(mPDAI <5且下降≥2分)。
- 第16周和第48周均有54.5%的患者达到应答(mPDAI下降≥2分)。
- mPDAI中位数由基线8(四分位距7-10)降至第16周7(四分位距4-9)(P = .007)和第48周4(四分位距1.75-7.25)(P < .001)。
- 临床mPDAI亚评分由3.5(四分位距2-4)降至第16周2(四分位距1-3)(P = .009)和第48周1(四分位距0-2.25)(P = .001)。
- 内镜mPDAI亚评分由5.5(四分位距4-6)降至第16周4(四分位距3-6)(P = .032)和第48周3(四分位距1.75-4.25)(P = .001)。
关键数值与推荐
- 主要终点:第16周达到无激素缓解(mPDAI <5且下降≥2分)的患者比例为27.3%。
- 次要终点:第48周缓解患者比例为36.4%;第16周和第48周应答患者比例均为54.5%。
- 给药方案:基线静脉给予乌司奴单抗约6 mg/kg,此后每8周皮下注射90 mg。
临床怎么用
- 作者认为乌司奴单抗对约一半的慢性储袋炎患者有效,因此应将其纳入慢性储袋炎的治疗流程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Seventeen percent of patients with ulcerative colitis that undergo proctocolectomy with pouch surgery will develop chronic pouchitis. We evaluated the efficacy of ustekinumab for these patients. METHODS: We performed a prospective study of patients with chronic pouchitis receiving ustekinumab intravenously at baseline (∼6 mg/kg) and 90 mg ustekinumab subcutaneously every 8 weeks thereafter. The Modified Pouchitis Disease Activity Index (mPDAI) was assessed at baseline and weeks 16 and 48. The primary endpoint was the proportion of patients achieving steroid-free remission (mPDAI <5 and reduction by ≥2 points) at week 16. Secondary endpoints included the proportion of patients achieving remission at week 48, the proportion of patients achieving response (reduction of mPDAI by ≥2 points) at weeks 16 and 48, and change in mPDAI. RESULTS: We enrolled 22 patients (59% male; median age, 42.2 years). Remission was achieved in 27.3% at week 16 and 36.4% at week 48. Response was achieved in 54.5% both at weeks 16 and 48. The median mPDAI decreased from 8 (interquartile range [IQR], 7-10) to 7 (IQR, 4-9) at week 16 (P = .007) and 4 (IQR, 1.75-7.25) at week 48 (P < .001). The clinical mPDAI subscore decreased from 3.5 (IQR, 2-4) to 2 (IQR, 1-3) at week 16 (P = .009) and 1 (IQR, 0-2.25) at week 48 (P = .001). The endoscopic mPDAI subscore decreased from 5.5 (IQR, 4-6) to 4 (IQR, 3-6) at week 16 (P = .032) and 3 (IQR, 1.75-4.25) at week 48 (P = .001). CONCLUSION: Ustekinumab was efficacious in one-half of the patients suffering from chronic pouchitis. Ustekinumab should therefore be positioned in the treatment algorithm of chronic pouchitis. (ClinicalTrials.gov Number NCT04089345).
引用
- Outtier A, Louis E, Dewit O, et al. Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study. Clin Gastroenterol Hepatol. 2024. PMID: 38750870. doi:10.1016/j.cgh.2024.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。